

A new therapy for global prevention of haemolytic disease of the newborn (HDFN)

The Problem


- Current anti-RhD treatment for HDFN is highly effective, but relies on blood donations
- Globally only 50% of women have access to HDFN preventative treatment
- HDFN is 200 times higher in developing countries
- In developed countries (e.g US), only 65% pregnant women receives prophylaxis
- Treatment rely on availability of specific donors and carries disease transmission risks
- Ethical concerns regarding paid blood donations in marginalised communities
- Consensus that the current system for supplying anti-RhD is unsustainable

The Solution

- Standardised, scalable and reliable **synthetic** treatment
- Treatment which is independent of blood donations
- Guarantee the quality and supply of anti-RhD prophylaxis globally

Our Program

- A collaborative project with Australian Red Cross Lifeblood, which operates the anti-RhD program in Australia
- Identified a pool of functional and specific RhD antibodies (16 antibodies) and a provisional patent filed
- Assessed in vitro functional assays for individual antibodies
- Seeking- Co-development opportunity and funding for in vivo validation of the antibody pool, preclinical studies and further development (manufacturing, regulatory guidance, clinical trials)



Our Team

Prof Ian Wicks, Lab Head (WEHI)

Dr Behnaz Heydarchi (WEHI)

Prof David Irving, Research Director (Australian Red Cross Lifeblood)

Dr Onisha Patel, Business Development Manager,
patel.o@wehi.edu.au